Moderna and Merck personalized cancer vaccine succeeds in late-stage trial

A personalized mRNA vaccine from Moderna and Merck, combined with Keytruda, met its main goal in a late-stage clinical trial for melanoma. The treatment significantly helped prevent high-risk skin cancer from returning compared to standard therapy.